Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer

(2014) Z. Yu et al.   CLINICAL CANCER RESEARCH

Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling

(2014) Mari Masuda et al.   MOLECULAR & CELLULAR PROTEOMICS

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer

(2014) Masaki Shiota et al.   PROSTATE

HnRNP C, YB-1 and hnRNP L coordinately enhance skipping of human MUSK exon 10 to generate a Wnt-insensitive MuSK isoform

(2014) Farhana Nasrin et al.   Scientific Reports

A simple model to explain evolutionary trends of eukaryotic gene architecture and expression

(2013) Francesco Catania et al.   BIOESSAYS

Mutual Regulation between Raf/MEK/ERK Signaling and Y-Box-Binding Protein-1 Promotes Prostate Cancer Progression

(2013) K. Imada et al.   CLINICAL CANCER RESEARCH

Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer

(2013) M. Shiota et al.   CLINICAL CANCER RESEARCH

Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration

(2013) Masaki Shiota et al.   CURRENT CANCER DRUG TARGETS

Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer

(2013) Kathrine Røe et al.   PLoS One

Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation

(2013) N Fujimoto et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

Functional coupling of transcription and splicing

(2012) Marta Montes et al.   GENE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

YB-1 binds to CAUC motifs and stimulates exon inclusion by enhancing the recruitment of U2AF to weak polypyrimidine tracts

(2012) Wen-Juan Wei et al.   NUCLEIC ACIDS RESEARCH

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

(2012) A Astanehe et al.   ONCOGENE

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

(2012) Y Li et al.   ONCOGENE

Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity: Figure 1.

(2011) Marianne D. Sadar   CANCER RESEARCH

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

(2011) Elahe A. Mostaghel et al.   CLINICAL CANCER RESEARCH

Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer

(2011) Masaki Shiota et al.   CURRENT CANCER DRUG TARGETS

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression

(2011) M. Shiota et al.   ENDOCRINE-RELATED CANCER

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2011) Nicolas Mottet et al.   EUROPEAN UROLOGY

Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer

(2011) Masaki Shiota et al.   FREE RADICAL BIOLOGY AND MEDICINE

SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

(2011) Ming Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target

(2011) Masaki Shiota et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Antioxidant Therapy Alleviates Oxidative Stress by Androgen Deprivation and Prevents Conversion From Androgen Dependent to Castration Resistant Prostate Cancer

(2011) Masaki Shiota et al.   JOURNAL OF UROLOGY

Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer

(2011) Eiji Kashiwagi et al.   PROSTATE

An update on androgen deprivation therapy for prostate cancer

(2010) Nima Sharifi et al.   ENDOCRINE-RELATED CANCER

Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression

(2009) M Shiota et al.   ONCOGENE

Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice

(2008) Cathy Lee et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer

(2008) Robert W. Ross et al.   JOURNAL OF CLINICAL ONCOLOGY